Portfolio Finder

Lipocalyx Exit

Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.

HTGF-Manager: Ulrike Kalapis
In portfolio 14. Jul 2011 – 07. Apr 2021

SIRION Biotech Exit

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

HTGF-Manager: Marco Winzer
In portfolio 04. Sep 2007 – 22. Jun 2021